AltStreet
EDGAR Verified
Primary Source · SEC.gov

Analytical Biotech Fund, LP

CIK 0002108298Fund Vehicle2026 vintage506(b), 3(c)(1)

Raised

Pre-open

Investors

—

Min Invest

$500,000

AltStreet Analysis

·

Generated from EDGAR primary sources

Analytical Biotech Fund, LP is a Delaware limited partnership filing under Rule 506(b) and Section 3(c)(1), indicating a private hedge fund structure. The filing is pre-open with no capital raised or investor count disclosed; minimum investment is set at $500K. The fund is promoted by Syno Partners, LLC and Syno Capital, LLC, with executive officers Joseph Weilgus and Justin Xiang.

This longevity biotech fund employs a 506(b) exemption typical of manager-relationship-driven offerings that prohibit general solicitation. The $500K minimum investment sits at the lower end of institutional-grade biotech funds, which commonly require $1M+ for specialized life sciences strategies.

Data Flags

generalPre-open filing with no first sale date and no capital raised, yet minimum investment and investor eligibility parameters are fully defined
related_personsTwo separate promoter entities listed (Syno Partners, LLC and Syno Capital, LLC) with overlapping roles; unusual to declare dual promoters without clarification of respective functions

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0002108298
Entity NameAnalytical Biotech Fund, LP
Exemption506(b), 3(c)(1)
First Sale Date—
Filing DateMarch 31, 2026
Accession Number0002108298-26-000001
Total Amount Sold—
Total Investors—
Minimum Investment$500,000
Securities TypePooled Investment Fund
State of IncorporationNot specified
Amendment CountOriginal filing only

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

n/a Syno Partners, LLC

Promoter · New York, NY

n/a Syno Capital, LLC

Promoter · New York, NY

Joseph Weilgus

Executive Officer · New York, NY

Justin Xiang

Executive Officer · New York, NY

Is this your offering?

Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.

Claim Profile — FreeGet Verified — $2,400/yr

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.